Stock data
Aquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics, Inc. (AQST) reported revenue of US$44.55M and net income of -US$83.78M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$44.55M | — | -US$71.05M | -US$83.78M | — |
| 2024 | US$57.56M | — | -US$30.77M | -US$44.14M | — |
| 2023 | US$50.58M | — | -US$15.10M | -US$7.87M | — |
| 2022 | US$47.68M | — | -US$42.07M | -US$54.41M | — |
| 2021 | US$50.83M | — | -US$34.68M | -US$70.54M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$13.82M | -US$22.86M | — |
| 2026-03-31 | US$14.45M | -US$8.06M | — |
| 2025-12-31 | US$13.02M | -US$31.86M | — |
| 2025-09-30 | US$12.81M | -US$15.45M | — |
| 2025-06-30 | US$10.00M | -US$13.55M | — |
| 2025-03-31 | US$8.72M | -US$22.93M | — |
| 2024-12-31 | US$11.87M | -US$17.05M | — |
| 2024-09-30 | US$13.54M | -US$11.51M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.